69 related articles for article (PubMed ID: 1462678)
1. [Pravastatin, a new cholesterol synthesis inhibitor for lowering increased serum cholesterol].
Hoppichler F; Lechleitner M; Patsch JR
Z Gesamte Inn Med; 1992 Nov; 47(11):523-7. PubMed ID: 1462678
[TBL] [Abstract][Full Text] [Related]
2. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
[TBL] [Abstract][Full Text] [Related]
3. Long-term experience with pravastatin in clinical research trials.
McGovern ME; Mellies MJ
Clin Ther; 1993; 15(1):57-64. PubMed ID: 8458055
[TBL] [Abstract][Full Text] [Related]
4. [Effects of pravastatin on serum lipids, apoproteins, and lipoprotein (a) in primary hypercholesterolemia].
Galetta F; Sampietro T; Basta G; Bionda A
Minerva Med; 1994 Jun; 85(6):321-6. PubMed ID: 8084435
[TBL] [Abstract][Full Text] [Related]
5. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
[TBL] [Abstract][Full Text] [Related]
6. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Stender S; Schuster H; Barter P; Watkins C; Kallend D;
Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
[TBL] [Abstract][Full Text] [Related]
7. Prevention of coronary heart disease through cholesterol reduction.
Grundy SM
Am Fam Physician; 1997 May; 55(6):2250-8. PubMed ID: 9149652
[TBL] [Abstract][Full Text] [Related]
8. Simvastatin versus pravastatin: efficacy and tolerability in patients with primary hypercholesterolemia.
Malini PL; Ambrosioni E; De Divitiis O; Di Somma S; Rosiello G; Trimarco B
Clin Ther; 1991; 13(4):500-10. PubMed ID: 1934003
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II.
Arch Intern Med; 1993 Jun; 153(11):1321-9. PubMed ID: 8507122
[TBL] [Abstract][Full Text] [Related]
10. Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
Nissen SE
Am J Med; 2005 Dec; 118 Suppl 12A():22-7. PubMed ID: 16356804
[TBL] [Abstract][Full Text] [Related]
11. [Pravastatin in patients with cardiac risk factors. Effects of pravastatin in patients with total serum cholesterol concentrations of 200 to 300 mg/dl (5.2 to 7.8 mmol/l) and two additional atherosclerosis risk factors. Pravastatin Multinational Study Group for Cardiac Risk Patients].
Fortschr Med; 1994 Feb; 112(5):57-64. PubMed ID: 8163252
[TBL] [Abstract][Full Text] [Related]
12. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
13. [Pravastatin in the treatment of primary hypercholesterolemia: a Swiss multicenter study].
Ferrari P; Weidmann P; Riesen WF; Martius F; Luban S; Pasotti E; Erne P; Fragiacomo C; Noseda G; Reutter F
Schweiz Med Wochenschr; 1993 Sep; 123(37):1736-41. PubMed ID: 8211024
[TBL] [Abstract][Full Text] [Related]
14. [Statins in primary prevention of coronary heart disease].
Paulweber B
Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
[TBL] [Abstract][Full Text] [Related]
15. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
Nissen SE
Am J Cardiol; 2005 Sep; 96(5A):61F-68F. PubMed ID: 16126025
[TBL] [Abstract][Full Text] [Related]
16. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.
Illingworth DR; Bacon S
Arteriosclerosis; 1989; 9(1 Suppl):I121-34. PubMed ID: 2492189
[TBL] [Abstract][Full Text] [Related]
17. Electrocardiographic events and cholesterol reduction with pravastatin in patients with hypercholesterolemia: the Hokuriku Lipid Coronary Heart Disease Study-Pravastatin Atherosclerosis Trial.
Shimizu M; Koizumi J; Miyamoto S; Origasa H; Mabuchi H;
Int J Cardiol; 2005 Mar; 99(3):395-401. PubMed ID: 15771919
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
[TBL] [Abstract][Full Text] [Related]
19. Pravastatin: a new drug for the treatment of hypercholesterolemia.
Jungnickel PW; Cantral KA; Maloley PA
Clin Pharm; 1992 Aug; 11(8):677-89. PubMed ID: 1511541
[TBL] [Abstract][Full Text] [Related]
20. Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment.
Lahoz C; Peña R; Mostaza JM; Laguna F; García-Iglesias MF; Taboada M; Pintó X
Metabolism; 2005 Jun; 54(6):741-7. PubMed ID: 15931608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
